AGEN1223 / Gilead, Agenus - LARVOL DELTA

A Study in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=19 | Terminated | Sponsor: Agenus Inc. | N=82 ➔ 19 | Trial completion date: Feb 2024 ➔ Sep 2021 | Active, not recruiting ➔ Terminated | Trial primary completion date: Feb 2023 ➔ Apr 2021; Strategic business decision.

Combination therapy • Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Oncology • Solid Tumor

A Study in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - P1; N=82; Active, not recruiting; Sponsor: Agenus Inc.; Recruiting ➔ Active, not recruiting; N=40 ➔ 82

Clinical • Combination therapy • Enrollment change • Enrollment closed • Oncology • Solid Tumor

A Study in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - P1; N=40; Recruiting; Sponsor: Agenus Inc.; Trial primary completion date: Jan 2024 ➔ Feb 2023

Clinical • Trial primary completion date

Agenus commences phase 1 trial with AGEN1223 (PRNewswire) - "Agenus Inc...announced the dosing of the first patient with AGEN1223...The first patient was infused in December 2019 and the trial is underway with a plan to initiate combinations with balstilimab, Agenus' investigational PD-1 inhibitor, in 2020....Dr. Anthony El-Khoueiry...dosing this first patient. Dr. El-Khoueiry is the phase I program director and a recognized expert in early drug development and translational medicine with a focus in hepatobiliary (liver, gall bladder, and bile duct) and pancreatic cancers....The Phase 1, open-label, multicenter study is designed to assess the maximum tolerated dose of AGEN1223 in subjects with advanced solid tumors."

Enrollment open • Trial status

A Study in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - P1; N=40; Recruiting; Sponsor: Agenus Inc.

Clinical • New P1 trial

Agenus closes $150 million immuno-oncology transaction with Gilead (PRNewswire) - "Under the terms of the agreement, Agenus receives $150 million in connection with closing, which includes a $120 million upfront cash payment and a $30 million equity investment. The agreement also includes approximately $1.7 billion in potential future fees and milestones. Gilead received worldwide exclusive rights to AGEN1423. Gilead also received the exclusive option to license two additional programs: AGEN1223 and AGEN2373. Agenus has filed the IND for AGEN1223 and has a planned IND filing for AGEN2373 in the first half of 2019."

IND • Licensing / partnership